 This study demonstrated that AT7519, a cyclic dependent kinase inhibitor, CDKI, was able to reduce the concentration of acetaminophen, APAP, in mice. However, it did not correlate with any markers of hepatic damage or proliferation, suggesting that AT7519 may have a protective role against APAP toxicity. This article was authored by Jennifer A. Cartwright, Joanna P. Simpson, Natalie Z. and M. Homer and others.